Becton Dickinson and Company (BDX) has been under a strong bear grip, hence the stock is down -1.64% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.09% in the past 1 week. The stock has risen by 0.14% in the past week indicating that the buyers are active at lower levels, but the stock is down -0.63% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 0.48% and the 50-Day Moving Average is 1.2%. Becton Dickinson and Company (NYSE:BDX): On Fridays trading session , Opening price of the stock was $176.22 with an intraday high of $176.49. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $173.66. However, the stock managed to close at $173.98, a loss of 1.54% for the day. On the previous day, the stock had closed at $176.71. The total traded volume of the day was 598,850 shares.
The company Insiders own 1.6% of Becton Dickinson and Company shares according to the proxy statements. Institutional Investors own 81.87% of Becton Dickinson and Company shares. During last six month period, the net percent change held by insiders has seen a change of -21.24%. Also, Major Brokerage house, UBS maintains its ratings on Becton Dickinson and Company (NYSE:BDX). In the latest research report, UBS raises the target price from $182 per share to $195 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on August 5, 2016.
Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Companys Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Companys BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Companys BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.